Q-omics provides the consensus-scored ACTG1P24 profile across patient tissues and cancer cell-line models. ACTG1P24 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACTG1P24 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ACTG1P24 RNA expression shows 17,045 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ACTG1P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTG1P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTG1P24 survival associations across molecular data types. ACTG1P24 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTG1P24 RNA expression–survival associations across cancer types. High ACTG1P24 expression shows unfavorable associations in KIRC, STAD, LGG and UVM, but favorable associations in PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACTG1P24 RNA expression.
This table summarizes ACTG1P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTG1P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTG1P24 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, UCEC and CHOL. The THCA box plot shows higher ACTG1P24 RNA expression in normal versus tumor tissue (log2 FC = −0.198, t-test p < 0.001).
This table shows molecular features associated with ACTG1P24 in patient tissues and cancer cell lines. In patient samples, ACTG1P24 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
